CNS Antigen ELISPOT Assays for Predicting MS Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the ability to predict whether a patient with clinically-isolated syndrome (CIS) or radiologically-isolated syndrome (RIS) will develop multiple sclerosis (MS) or respond to immune modulatory therapy, and there are no effective ways to predict disease progression or relapse in MS patients.
Innovation Solution
A method using an ELISPOT assay to detect B-lymphocyte or plasma cell antibody binding to whole brain lysate in peripheral blood mononuclear cells (PBMCs) to diagnose MS, predict disease progression, and determine responsiveness to immune modulatory therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for MS, then general diagnosis can be made, but prediction of disease progression and treatment responsiveness is not possible
Solution Approach 1:
The invention segments the diagnostic approach by distinguishing between different B cell subsets (naive, memory, plasma cells) and their specific antigen reactivities. This segmentation enables precise prediction of disease progression and treatment responsiveness by analyzing specific subsets rather than treating all B cells uniformly, thereby resolving the contradiction between general diagnostic capability and specific predictive information.
Solution Approach 2:
The invention performs preliminary characterization of B cell repertoires and antigen specificities before disease progression occurs or before treatment is initiated. By conducting ELISPOT assays and flow cytometry analyses at baseline, the method predicts future disease course and treatment response, addressing the information loss about disease progression that occurs with conventional reactive diagnostic approaches.
2Adaptability or versatility
If immune modulatory therapy is administered without patient selection, then treatment can be provided to all patients, but treatment responsiveness varies remarkably between patients
Solution Approach 1:
The invention introduces dynamic adaptation into treatment by using baseline B cell repertoire characterization to customize treatment selection for each patient. The method dynamically matches patients to appropriate immune modulatory therapies based on their specific B cell profiles, antigen specificities, and disease subtype classifications, thereby resolving the contradiction between universal treatment availability and individualized treatment effectiveness.
Solution Approach 2:
The invention changes the parameter of treatment selection from population-based to individual-based by measuring specific B cell parameters (subset frequencies, antigen reactivities, clonal expansions). These parameter changes enable reliable prediction of treatment responsiveness and allow customization of immunotherapy regimens to match each patient's immunopathogenic profile, addressing the remarkable variability in treatment response.
3Adaptability or versatility
If B cell subsets and antigen specificities are not characterized, then diagnostic process is simpler, but subpopulations of MS patients with different immune pathogenesis cannot be identified
Solution Approach 1:
The invention achieves multi-functionality by using a unified diagnostic platform (ELISPOT assays combined with flow cytometry) that simultaneously characterizes B cell subsets, antigen specificities, and disease subtypes. This universal approach identifies various MS patient subpopulations (antibody-mediated, T cell-driven, oligodendrogliopathy) without requiring separate specialized tests, resolving the contradiction between comprehensive patient classification and diagnostic simplicity.
Solution Approach 2:
The invention merges multiple characterization techniques (ELISPOT spot counting, flow cytometry phenotyping, antigen panel testing) into an integrated diagnostic workflow. By combining these methods to simultaneously assess B cell subsets and antigen reactivities, the invention identifies distinct MS subpopulations while managing assay complexity through standardized protocols and automated analysis, addressing the need for comprehensive patient stratification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides accurate diagnosis and prediction of MS development and therapeutic responsiveness, offering guidance for targeted treatment strategies.
Implementation Method 1
detecting a B-lymphocyte or plasma cell antibody binding to said whole brain lysate using an ELISPOT assay
Data Source
Figure 1A~1D
Figure 2A~2D
Figure 2E~2H
AI summary
Embodiments of this invention include methods for detecting in vitro the presence in peripheral blood mononuclear cells (PBMCs), and in serum or plasma, of antibodies reactive to and of lymphocytes that are responsive to CNS antigens associated with Multiple Sclerosis (MS). These CNS antigens include, but are not limited to whole brain lysate and the myelin antigens myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), MOG peptides (MOGps), proteolipid protein (PLP), and PLP peptides (PLPps). Stimulating PBMCs from patients with MS by CNS antigens cause B-lymphocytes to produce antibodies specific for CNS antigen, and causes T-lymphocytes to produce T-lymphocyte-specific cytokines, including interferon gamma (IFN-γ), interleukin-2 (IL-2), or interleukin-17 (IL-17). In contrast, stimulating PBMCs from subjects without MS do not produce such responses. In patients with clinically-isolated syndrome (CIS) or radiologically-isolated syndrome (RJS), the presence of PBMC responsive to CNS antigens can indicate which patients are likely to develop MS. The magnitude of the CNS antigen-specific response in patients with definite MS or in patients with CIS or RIS can indicate the likelihood that a given patient will develop a relapse and the responsiveness to and the success of immune modulatory treatment.